

DEC 27 2002

1810A-045 (81841.0192)

1641
Boxsey

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert S. Matson

Serial No: 09/872,052

Filed: May 31, 2001

For: IMMOBILIZATION OF UNMODIFIED BIOPOLYMERS
TO ACYL FLUORIDE ACTIVATED SUBSTRATES

Art Unit: 1641

Examiner: Gabel, Gailene

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
 Commissioner for Patents
 Washington D.C. 20231, on
 December 20, 2002

Date of Deposit
 Nilka Mickey

Name *Nilka Mickey* 12/20/02
 Signature Date

Commissioner for Patents
 Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an amendment in the above-identified application. Also enclosed are:

- Amendment
- Copy of Notice to Comply With Requirements...;
- Diskette containing sequence listing;
- Print out of Sequence Listing; and
- Verified Statement Concerning Sequence Listing.
- No additional fee is required.
- A check in the amount of \$____ to cover the additional claims fee is enclosed. **A copy of this sheet is enclosed.**
- A check in the amount of \$____ to cover the extension fee is enclosed. **A copy of this sheet is enclosed.**
- The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1314. **A copy of this sheet is enclosed.**
- Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims
- Any patent application processing fees under 37 C.F.R. § 1.17

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

Date: December 20, 2002

Biltmore Tower
 500 South Grand Avenue, Suite 1900
 Los Angeles, California 90071
 Telephone: 213 337-6700
 Facsimile: 213 337-6701

Respectfully submitted,
 HOGAN & HARTSON L.L.P.

By:

William E. Thomson
 William E. Thomson, Jr.
 Registration No. 20,719
 Attorney for Applicant(s)



UNITED STATES PATENT AND TRADEMARK OFFICE

RECKMAN COOTDRE
WY
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/872,052	05/31/2001	Robert S. Matson	1810A-045 (81841.0192)	8141

26021 7590 11/25/2002
HOGAN & HARTSON L.L.P.
500 S. GRAND AVENUE
SUITE 1900
LOS ANGELES, CA 90071-2611



EXAMINER

GABEL, GAILENE

ART UNIT	PAPER NUMBER
1641	P

DATE MAILED: 11/25/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

JAN 02 2003

1600/2900

RECEIVED
DEC 02 2002
DOCKETING



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./CONTROL NO. 09/872,052	FILING DATE 5/31/02	FIRST NAMED INVENTOR /PATENT IN REEXAMINATION MATSON et al.	ATTORNEY DOCKET NO. 1810A-045
---	------------------------	--	----------------------------------

EXAMINER

Gailene R. Gabel

ART UNIT
1641

PAPER
6



RECEIVED

DATE MAILED: JAN 02 2003

TECH CENTER 1600/2900

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents


This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the one month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R. Gabel whose telephone number is (703) 305-0807.

CHRISTOPHER L. CHIN
PRIMARY EXAMINER
GROUP 1800/641

11/19/02



DEC 27 2002
Notice to Comply

Application N
09/872,052

Applicant(s)
MATSON et al.

Examiner
Gailene R. Gabel

Art Unit
1641
Paper No. 6

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The nucleotide sequences at page 18, lines 4-6 of the specification are each not identified by a sequence identifier, i.e. SEQ ID NO.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patent Software.....703-306-2600

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY